Skip navigation

AstraZeneca taps AI for drug discovery in deal with BERG

AstraZeneca has forged a research collaboration with Boston-based BERG, a specialist in artificial intelligence for drug hunting, in the latest sign of big pharma’s interest in using supercomputers for drug discovery.

The tie-up will focus on finding and evaluating novel ways of treating Parkinson’s disease and other neurological disorders.

View full article: